- Companies
- Vitestro
Vitestro Funding, Investors & Competitors
Vitestro has raised $104M across 3 funding rounds, most recently a $70M Series B in March 2026.
Last Vitestro funding round
$70M
Series B · Mar 2026
Cumulative funding Vitestro raised
$104M
across 3 funding rounds
Key investors in Vitestro
Sonder Capital
European Innovation Council
NYBC Ventures
InterVest Co.
Mayo Clinic
Invest-NL
PGGM Investments
LabCorp Venture Fund
About Vitestro
Vitestro is an Eindhoven-headquartered medtech company pioneering autonomous robotic phlebotomy devices that perform blood draws without needles visible to patients. The Vitestro One system uses ultrasound-guided lancets to collect up to 12 milliliters of blood in seconds, reducing pain and vein misses by 80 percent. Deployed in over 20 hospitals across Europe and the U.S., including Erasmus MC, the technology integrates with EHR systems for seamless lab workflows. Founded in 2019 by Eindhoven University alumni, Vitestro raised €25 million in Series A funding.
Founded
2017
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Product sales
Vitestro Funding History
Vitestro has raised a total of $104M across 3 funding rounds.
Vitestro's first fundraising round was a $13M Series A in March 2023. The most recent completed round was a $70M Series B in March 2026.
Vitestro funding rounds
| Date | Stage | Investors | Raised | Deal Summary |
|---|---|---|---|---|
| Mar 2026 | Series B | European Innovation Council; Sonder Capital; MGFO; Puma Venture Capital; ROM Utrecht Region; PGGM Investments; InterVest Co.; LabCorp Venture Fund; NYBC Ventures; Sutter Health; Mayo Clinic; Intervest | $70M | - |
| Apr 2024 | Series A | NYBC Ventures (lead); Sonder Capital (lead); European Innovation Council; Invest-NL | $21M | Vitestro is a pioneering autonomous blood drawing company based in Utrecht, The Netherlands, developing Aletta, the world's first fully autonomous robotic device for diagnostic blood collection. The device handles the complete blood draw process from tourniquet application to bandaging using artificial intelligence, near-infrared imaging, ultrasound, and Doppler imaging technology to identify veins accurately and address cases where traditional phlebotomy methods fail. On April 30, 2024, Vitestro announced the close of a $22 million (€20 million) Series B funding round co-led by return investor Sonder Capital and new investor NYBC Ventures, with participation from Invest-NL, the European Innovation Council Fund, and existing private investors. The round was oversubscribed and brought Vitestro's total funding raised to $50 million (€46 million) from both equity investments and grant funding. The capital was designated to accelerate Vitestro's commercialization efforts in Europe and facilitate organizational expansion into the U.S. market, with the company aiming to obtain CE approval for its device by the end of 2024 and commence deployment simultaneously. Vitestro was also leading the A.D.O.P.T. trial, described as the world's largest evaluation of autonomous blood drawing devices, with early feedback from hospitals, staff, and patients reported as overwhelmingly positive. Dr. Fred Moll, co-founder of Intuitive Surgical and managing partner at Sonder Capital, highlighted the market opportunity, noting that diagnostic blood collection represents the highest-volume invasive medical procedure globally with billions of procedures performed annually, while laboratories face staffing challenges and capacity constraints. |
| Mar 2023 | Series A | Sonder Capital (lead); Addington Investment Group | $13M | Vitestro raised an undisclosed amount in a Series A round on March 21, 2023, with participation from Sonder Capital and Addington Investment Group. The Dutch medtech company develops the Aletta Autonomous Robotic Phlebotomy Device for automated blood collection using AI, near-infrared, ultrasound, and Doppler imaging. This round preceded a June 2023 incubator/accelerator and a $22M Series A-II on April 30, 2024, involving Sonder Capital, NYBC Ventures, European Innovation Council, and Invest-NL. Vitestro later secured a $70M oversubscribed Series B in March 2026 from investors including Labcorp Venture Fund, Mayo Clinic, Sutter Health, and existing backers like Sonder Capital and NYBC Ventures to advance FDA clearance, manufacturing scale-up, and global commercialization starting in Europe. |
Who has invested in Vitestro?
14 investors have backed Vitestro across its funding rounds, including Sonder Capital, European Innovation Council, NYBC Ventures, InterVest Co., Mayo Clinic and Invest-NL.
Lead investors include NYBC Ventures and Sonder Capital.
Vitestro Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 3 | Lead | Mar 2023 | ||
| 2 | Participant | Apr 2024 | ||
| 2 | Lead | Apr 2024 | ||
| 1 | Participant | Mar 2026 | ||
| 1 | Participant | Mar 2026 | ||
| 1 | Participant | Mar 2026 | ||
| 1 | Participant | Mar 2026 | ||
| 1 | Participant | Mar 2026 | ||
| 1 | Participant | Mar 2026 | ||
| 1 | Participant | Apr 2024 | ||
| 1 | Participant | Mar 2023 | ||
| 1 | Participant | Mar 2026 | ||
This data is available for Pro users. Sign up to see all 14 Vitestro investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialVitestro Competitors
Vitestro competitors include listed companies like Siemens, Johnson & Johnson, Roche and Thermo Fisher Scientific, and private ones like Biosplice Therapeutics and Neuralink.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Publicly listed | $91B | $15B | $234B | 2.9x | ||
| Publicly listed | $94B | $40B | $651B | 6.8x | ||
| Publicly listed | $77B | $26B | $351B | 4.9x | ||
| Publicly listed | $45B | $11B | $243B | 6.0x | ||
| Private | - | - | $12B | - | ||
| Private | - | - | $9B | - |
Vitestro Public Comps
Vitestro is still privately-owned, but its public comps include Samsung, Johnson & Johnson, Roche, Thermo Fisher Scientific, Siemens, Schneider Electric, Abbott, ABB, Hitachi and Danaher.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $243B | $67B | 4.4x | 2.4x | 15.8x | 4.4x | |||
| $94B | $40B | 7.2x | 6.8x | 17.0x | 18.3x | |||
| $77B | $26B | 5.0x | 4.9x | 14.6x | 12.4x | |||
| $45B | $11B | 6.3x | 6.0x | 26.8x | 23.6x | |||
| $91B | $15B | 3.0x | 2.9x | 18.1x | 15.7x | |||
| $46B | $9.5B | 4.3x | 3.9x | 21.0x | 18.4x | |||
| $44B | $12B | 4.6x | 4.2x | 17.4x | 15.8x | |||
| $33B | $6.9B | 5.4x | 4.9x | 25.9x | 22.6x | |||
This data is available for Pro users. Sign up to see all Vitestro competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Vitestro
| When was Vitestro founded? | Vitestro was founded in 2017. |
| Where is Vitestro headquartered? | Vitestro is headquartered in Utrecht, Netherlands. |
| Is Vitestro publicly listed? | No, Vitestro is a private, VC-backed company. |
| How much funding has Vitestro raised? | Vitestro has raised $104M across 3 funding rounds. |
| What was Vitestro's last funding round? | Vitestro's last funding round was a $70M Series B in March 2026. |
| Who are Vitestro's investors? | Vitestro's investors include Sonder Capital, European Innovation Council, NYBC Ventures, MGFO, Puma Venture Capital, ROM Utrecht Region, PGGM Investments, InterVest Co., LabCorp Venture Fund, Invest-NL and 4 others. |
| Which companies are comparable to Vitestro? | Companies comparable to Vitestro include Siemens, Johnson & Johnson, Roche, Thermo Fisher Scientific, Biosplice Therapeutics and Neuralink. |
See companies similar to Vitestro
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




